Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B London

Showing results (211-220 of 310) with videos related to

Pageof 31
Sort By:
Oncotarget|July 25, 2016
MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4Chengyuan Xue, Denise M T Yu, Samuele Gherardi, et al.
Plos One|November 20, 2009
Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survivalIsabella Bray, Kenneth Bryan, Suzanne Prenter, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2010
Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group ProjectVeronica Moroz, David Machin, Andreas Faldum, et al.
Cancer|July 12, 2017
Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology GroupKevin Campbell, Julie M Gastier-Foster, Meegan Mann, et al.
The Lancet. Oncology|May 28, 2017
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trialRajen Mody, Arlene Naranjo, Collin Van Ryn, et al.
Cancer Cell|December 18, 2014
ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastomaScott C Bresler, Daniel A Weiser, Peter J Huwe, et al.
The New England Journal of Medicine|October 1, 2010
Outcome after reduced chemotherapy for intermediate-risk neuroblastomaDavid L Baker, Mary L Schmidt, Susan L Cohn, et al.
Bone Marrow Transplantation|January 22, 2013
A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1A E Seif, A Naranjo, D L Baker, et al.
British Journal of Cancer|June 3, 2015
Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group studyL L Wang, R Teshiba, N Ikegaki, et al.
Cancer|August 1, 2013
Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology GroupLarry L Wang, Rie Suganuma, Naohiko Ikegaki, et al.
Pageof 31

Showing results (211-220 of 310) with videos related to

Sort By:
Pageof 31
Oncotarget|July 25, 2016
MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4Chengyuan Xue, Denise M T Yu, Samuele Gherardi, et al.
Plos One|November 20, 2009
Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survivalIsabella Bray, Kenneth Bryan, Suzanne Prenter, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2010
Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group ProjectVeronica Moroz, David Machin, Andreas Faldum, et al.
Cancer|July 12, 2017
Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology GroupKevin Campbell, Julie M Gastier-Foster, Meegan Mann, et al.
The Lancet. Oncology|May 28, 2017
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trialRajen Mody, Arlene Naranjo, Collin Van Ryn, et al.
Cancer Cell|December 18, 2014
ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastomaScott C Bresler, Daniel A Weiser, Peter J Huwe, et al.
The New England Journal of Medicine|October 1, 2010
Outcome after reduced chemotherapy for intermediate-risk neuroblastomaDavid L Baker, Mary L Schmidt, Susan L Cohn, et al.
Bone Marrow Transplantation|January 22, 2013
A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1A E Seif, A Naranjo, D L Baker, et al.
British Journal of Cancer|June 3, 2015
Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group studyL L Wang, R Teshiba, N Ikegaki, et al.
Cancer|August 1, 2013
Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology GroupLarry L Wang, Rie Suganuma, Naohiko Ikegaki, et al.
Pageof 31